Posts by tag
HER2
Antibody-drug conjugates make their mark at ASCO
Reports of the results of two antibody-drug conjugates (ADCs), one for HER-low metastatic breast cancer, the other for metastatic lung cancer resistant to EGFR inhibitors, highlight the advances being made in this type of treatment. The DESTINY-Breast04 study, presented at…
Lumpectomy as effective as mastectomy in young breast cancer patients
Women under 40 with non-metastatic breast cancer experience similar survival regardless of whether they are treated with mastectomy or lumpectomy. The abstract presented at the American Society of Breast Surgeons annual meeting, held in Las Vegas, April 2022, showed that…
What’s new in lung and colorectal cancer? reports from ESMO 2021
New research findings presented at ESMO 2021 show progress in adjuvant treatment for non-small-cell lung cancer (NSCLC), a novel inhibitor for HER2+ NSCLC patients, and the latest from the FOCUS 4 adaptive, molecularly stratified, umbrella trial platform, set up to…